

OMEROS CORP  
Form 8-K  
October 05, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 4, 2018**

**OMEROS CORPORATION**

**(Exact name of Registrant as Specified in Its Charter)**

**Washington**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-34475**  
**(Commission**  
  
**File Number)**

**91-1663741**  
**(IRS Employer**  
  
**Identification No.)**

**98119**

**201 Elliott Avenue West  
Seattle, WA**

**(Address of Principal Executive Offices)**

**(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (206) 676-5000**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On October 4, 2018, Omeros Corporation (the Company) received an order from the U.S. Securities and Exchange Commission (the SEC) extending a prior grant of confidential treatment. The order resulted from a routine request to extend a previous grant of confidential treatment that was soon to expire for certain information contained in two exhibits that were originally filed in connection with the Company's 2009 initial public offering. The SEC originally granted confidential treatment for this information on October 7, 2009 and subsequently extended the period of confidential treatment approximately every three years in orders dated September 16, 2012 and September 3, 2015. The applicable exhibits are incorporated by reference to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit  
Number**

- 10.1 Exclusive License and Sponsored Research Agreement between Omeros Corporation and Medical Research Council dated October 31, 2005 (incorporated by reference to Exhibit 10.31 to Amendment No. 5 to the Company's Registration Statement on Form S-1 (File No. 333-148572) filed with the SEC on September 16, 2009).
- 10.2 Amendment dated May 8, 2007 to Exclusive License and Sponsored Research Agreement between Omeros Corporation and the Medical Research Council dated October 31, 2005 (incorporated by reference to Exhibit 10.32 to the Company's Registration Statement on Form S-1 (File No. 333-148572) filed with the SEC on January 9, 2008).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OMEROS CORPORATION**

Date: October 5, 2018

By: /s/ Gregory A. Demopoulos  
Gregory A. Demopoulos, M.D.  
President, Chief Executive Officer and  
Chairman of the Board of Directors